Background: Cleft palate repair surgery may result in severe pain in the immediate postoperative period. This study aims to compare the effects of different doses of nalbuphine on postoperative analgesia in children with cleft palate.
Methods: From September 2019 to June 2021, 90 children (45 males and 45 females, 9-20 months old, ASA Ⅰ - Ⅱ) were selected for palatoplasty. They were randomly divided into three groups: control group (Group C), postoperative analgesia nalbuphine 0.05mg/kg/h (N1 group) and postoperative analgesia nalbuphine 0.075mg/kg/h (N2 group), 30 cases in each group. No analgesia drug was used in group C, and the postoperative analgesia regimen in group N1 and N2 was continuous pump infusion of nalbuphine 0.05mg/kg/h and 0.075mg/kg/h. For 24 hours. FLACC analgesia score and Ramsay Sedation score were recorded at 10min (T1), 30min (T2), 2h (T3), 12h (T4) and 24h (T5) after operation. Adverse reactions such as nausea, vomiting and respiratory depression were observed and recorded.
Results: Compared with group C, FLACC scores of N1 and N2 groups decreased significantly at T1-T5 (p<0.05); Ramsay Sedation score in N1 group was significantly higher at T3 and T4 (p<0.05), and that in N2 group was significantly higher at T1-T5 (p<0.05). Compared with N1 group, there was no significant difference in FLACC score in N2 group, and Ramsay Sedation score increased significantly at T5 (p<0.05).
Conclusion: Using Nalbuphine with 0.05mg/kg/h continuous for 24 hours for postoperative analgesia in children with cleft palate has better effect and less adverse reactions.
Trial registration: This study was registered at (ChiCTR1900027385,11/11/2019)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.